CR strengthens negotiating position, as company is no longer dependent on accepting a commercial deal to maintain viability. Same strategy employed by PAR last year. During negotiations with global Pharma, completed an $80M CR to demonstrate they could go it alone on a Stage 3 trial if need be. The other side needs to know you are able to walk away from a deal if the terms are not reasonable. RAP will be having many conversations with potential suitors who will have completed their own due diligence on RAP and be well aware of cash position and July options - and be negotiating on that basis. A successful CR will remove (or at least diminish) these two considerations.
RAP Price at posting:
24.0¢ Sentiment: Hold Disclosure: Held
